 | | Vol. 6.38 – 2 October, 2020 |
| |
|
|
| A microfluidic platform named IFlowPlate was engineered, which could be used to culture up to 128 independently perfused and vascularized colon organoids in vitro.
[Advanced Materials] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The expression of m6A associated enzymes and total m6A level were measured by Western Blotting analysis and m6A RNA Methylation Quantification Kit, respectively. Cell cycle was analyzed by flowcytometry. The interaction of IGF2BP3 and related targets was analyzed by RNA immunoprecipitation and m6A RNA immunoprecipitation assays.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| A1874-induced degradation of BRD4 protein and downregulated BRD-dependent genes in colon cancer cells. A1874-induced anti-colon cancer cell activity was more potent than the known BRD4 inhibitors. In BRD4-knockout colon cancer cells A1874 remained cytotoxic, indicating the existence of BRD4-independent mechanisms.
[Cell Death & Disease] |
|
|
|
| Researchers identified X-linked inhibitor of apoptosis (XIAP) as the main E3 ubiquitin ligase in colon cancer cells. O-GlcNAc transferase (OGT) catalyzed the O-GlcNAc modification of XIAP at serine 406 and this modification was required for the E3 ubiquitin ligase activity of XIAP toward specifically OGT. O-GlcNAcylation of XIAP suppressed colon cancer cell growth and invasion by promoting the proteasomal degradation of OGT.
[Cell Death & Disease] |
|
|
|
| Scientists suggest that LGR5/4‐induced NF‐κB signaling and WNT signaling may co‐regulate the growth of LGR5+ adult stem cells and intestinal crypts.
[FASEB Journal] |
|
|
|
| Gly‐Pro‐Ala (GPA) alleviated intestinal inflammation and oxidative stress by inhibiting NF‐κB activation. GPA bound to the ligand‐binding domain of Nur77 and stimulated its autotranscriptional activity to enhance its expression in intestinal epithelial cells. Furthermore, GPA activated the promoter of IκBα to increase its expression, resulting in the abolishment of the NF‐κB pathway.
[FASEB Journal] |
|
|
|
| Myocardin-related transcription factor A (MRTF-A) promoted migration and invasion of HT-29 cells in a TC10-like (TCL)-dependent manner. MRTF-A directly bound to the proximal TCL promoter in response to hypoxia to activate TCL transcription.
[Oncogenesis] |
|
|
|
| Investigators revealed that protein arginine methyltransferase 5 catalyzes methylation of Y-box binding protein 1 (YBX1) at arginine 205, an event that was critical for YBX1-mediated nuclear factor κB activation and its downstream target gene expression.
[Scientific Reports] |
|
|
|
| Using the enterohemorrhagic E. coli secreted cytotoxin, EspP to induce injury to human colonoids, researchers evaluated a simplified, epithelial regeneration model that lacks mesenchymal Wnts. They demonstrated that epithelial-produced WNT2B was upregulated following injury and essential for regeneration.
[iScience] |
|
|
|
|
| Recent studies investigating the role of MHC class II+ exosomes released by Intestinal epithelial cells report conflicting findings of either immune enhancing or immunosuppressive activities. In addition to modulating inflammatory responses, recent findings suggest that MHC class II expression by intestinal stem cells may elicit crosstalk that promotes epithelial renewal.
[Immunology] |
|
|
|
|
| Daiichi Sankyo Company, Limited announced the approval of ENHERTU®, a HER2 directed antibody drug conjugate, in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
[Daiichi Sankyo Ltd.] |
|
|
|
| Celyad Oncology will conduct the Phase Ib KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology’s investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI preconditioning chemotherapy, with MSD’s anti-PD-1 therapy, KEYTRUDA® in refractory metastatic colorectal cancer patients with microsatellite stable/ mismatch-repair proficient disease.
[Celyad Oncology] |
|
|
|
|
| 2021-04-11-2021-04-13 |
San Diego, California, United States |
|
|
|
|
|
| | Moffitt Cancer Center – Tempa, Florida, United States |
|
|
|
| | Chr. Hansen A/S – Hørsholm, Denmark |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | The University of Arizona – Tucson, Arizona, United States |
|
|
|
| | City of Hope – Monrovia, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
